The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Open accessAbstract
Liver cancer has the fourth highest mortality rate of all cancers worldwide, with hepatocellular carcinoma (HCC) being the most prevalent subtype. Despite great advances in systemic therapy, such as molecular-targeted agents, HCC has one of the worst prognoses due to drug resistance and frequent recurrence and metastasis. Recently, new therapeutic strategies such as cancer immunosuppressive therapy have prolonged patients’ lives, and the combination of an immune checkpoint inhibitor (ICI) and VEGF inhibitor is now positioned as the first-line therapy for advanced HCC. Since the efficacy of ICIs depends on the tumor immune microenvironment, it is necessary to elucidate the immune environment of HCC to select appropriate ICIs. In this review, we summarize the findings on the immune microenvironment and immunosuppressive approaches focused on monoclonal antibodies against cytotoxic T lymphocyte-associated protein 4 and programmed cell death protein 1 for HCC. We also describe ongoing treatment modalities, including adoptive cell transfer-based therapies and future areas of exploration based on recent literature. The results of pre-clinical studies using immunological classification and animal models will contribute to the development of biomarkers that predict the efficacy of immunosuppressive therapy and aid in the selection of appropriate strategies for HCC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“CTLA-4 was first cloned in 1987 as a novel molecule expressed on activated T cells [142] and was later shown to have an inhibitory function [143]; in 1996, it was found that the CTLA-4 antibody could suppress cancer growth in the mouse model [144].”
Background(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-5-642_1 · Cited by 2,081
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
The Liver as an Immunological Organ
Racanelli, V., & Rehermann, B. (2006) · Hepatology · doi:10.1002/hep.21060 · Cited by 1,377
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Liver immunology and its role in inflammation and homeostasis
Robinson, M. W., Harmon, C., & O’Farrelly, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.3 · Cited by 1,151 · cited 4×
“Compared with those in the spleen, hepatic my‐ eloid DCs also produce significantly more IL‐10 and suppress T cell activation [42,43].”
BackgroundInfluentialTumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
Sangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 980
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976 · cited 1×
“group with many M2 macrophages by activating the TGF-β pathway (exhausted), and a good prognosis has been found only in the active immune class [201].”
BackgroundLiver: An organ with predominant innate immunity
Gao, B., Jeong, W.-I., & Tian, Z. (2008) · Hepatology · doi:10.1002/hep.22034 · Cited by 952
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.040 · Cited by 852
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Duffy, A. G., Ulahannan, S. V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., Davis, J. L., Hughes, M. S., Heller, T., ElGindi, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.029 · Cited by 819
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 737
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.117 · Cited by 665
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Yau, T., Park, J. W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Han, K.-H., Harding, J. J., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.029 · Cited by 647
Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M. P., Greten, T. F., & Korangy, F. (2009) · Hepatology · doi:10.1002/hep.23054 · Cited by 643
Ormandy, L. A., Hillemann, T., Wedemeyer, H., Manns, M. P., Greten, T. F., & Korangy, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3232 · Cited by 642
Dixon, L. J., Barnes, M., Tang, H., Pritchard, M. T., & Nagy, L. E. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120026 · Cited by 628
Radaeva, S., Sun, R., Jaruga, B., Nguyen, V. T., Tian, Z., & Gao, B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.055 · Cited by 610 · cited 1×
“The TLR3 ligand, polyinosinic-polycytidylic acid, activates NK cells through high expression of TNF-α-related apoptosis-inducing ligand (TRAIL) and induces cell death of activated HSCs, thus resulting in reduced severity of liver fibrosis [47].”
BackgroundThe Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Böttcher, J. P., & Reis e Sousa, C. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.09.001 · Cited by 607
Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602
Immunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Caballero, O. L., & Chen, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01303.x · Cited by 554
Clinical significance of macrophage heterogeneity in human malignant tumors
Komohara, Y., Jinushi, M., & Takeya, M. (2014) · Cancer Science · doi:10.1111/cas.12314 · Cited by 551
Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity
Shetty, S., Lalor, P. F., & Adams, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0020-y · Cited by 523
Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
Lee, J. H., Lee, J.-H., Lim, Y.-S., Yeon, J. E., Song, T.-J., Yu, S. J., Gwak, G.-Y., Kim, K. M., Kim, Y. J., Lee, J. W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.055 · Cited by 503
Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496
Recognition of CD1d-restricted antigens by natural killer T cells
Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L., & Godfrey, D. I. (2012) · Nature Reviews Immunology · doi:10.1038/nri3328 · Cited by 460
Zhou, Y., Ren, H., Dai, B., Li, J., Shang, L., Huang, J., & Shi, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0965-2 · Cited by 456
Kurebayashi, Y., Ojima, H., Tsujikawa, H., Kubota, N., Maehara, J., Abe, Y., Kitago, M., Shinoda, M., Kitagawa, Y., & Sakamoto, M. (2018) · Hepatology · doi:10.1002/hep.29904 · Cited by 454
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448
Type IIFN s induce anti‐tumor polarization of tumor associated neutrophils in mice and human
Andzinski, L., Kasnitz, N., Stahnke, S., Wu, C., Gereke, M., von Köckritz‐Blickwede, M., Schilling, B., Brandau, S., Weiss, S., & Jablonska, J. (2016) · International Journal of Cancer · doi:10.1002/ijc.29945 · Cited by 430
Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States
Altekruse, S. F., Henley, J. S., Cucinelli, J. E., & McGlynn, K. A. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.11 · Cited by 429
Neutrophils in Homeostasis, Immunity, and Cancer
Nicolás-Ávila, J. Á., Adrover, J. M., & Hidalgo, A. (2017) · Immunity · doi:10.1016/j.immuni.2016.12.012 · Cited by 403
Immune Dysfunction and Infections in Patients With Cirrhosis
Bonnel, A. R., Bunchorntavakul, C., & Reddy, K. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.031 · Cited by 396
Fu, Y., Liu, S., Zeng, S., & Shen, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1396-4 · Cited by 390
Chew, V., Chen, J., Lee, D., Loh, E., Lee, J., Lim, K. H., Weber, A., Slankamenac, K., Poon, R. T. P., Yang, H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300509 · Cited by 359
Zhou, S.-L., Dai, Z., Zhou, Z.-J., Wang, X.-Y., Yang, G.-H., Wang, Z., Huang, X.-W., Fan, J., & Zhou, J. (2012) · Hepatology · doi:10.1002/hep.25907 · Cited by 356
Tumor-Associated Neutrophils in Cancer: Going Pro
Wu, L., Saxena, S., Awaji, M., & Singh, R. K. (2019) · Cancers · doi:10.3390/cancers11040564 · Cited by 337
Sander, L. E., Sackett, S. D., Dierssen, U., Beraza, N., Linke, R. P., Müller, M., Blander, J. M., Tacke, F., & Trautwein, C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091474 · Cited by 335
T Cells in Fibrosis and Fibrotic Diseases
Zhang, M., & Zhang, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01142 · Cited by 330
Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO
Li, T., Yang, Y., Hua, X., Wang, G., Liu, W., Jia, C., Tai, Y., Zhang, Q., & Chen, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.020 · Cited by 328
Yang, Y., Ye, Y.-C., Chen, Y., Zhao, J.-L., Gao, C.-C., Han, H., Liu, W.-C., & Qin, H.-Y. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0818-0 · Cited by 307
Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
Yan, W., Liu, X., Ma, H., Zhang, H., Song, X., Gao, L., Liang, X., & Ma, C. (2015) · Gut · doi:10.1136/gutjnl-2014-307671 · Cited by 306
Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches
Brodt, P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0460 · Cited by 301
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 294
The yin and yang of evasion and immune activation in HCC
Makarova-Rusher, O. V., Medina-Echeverz, J., Duffy, A. G., & Greten, T. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.038 · Cited by 293
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Guerriero, J. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.006 · Cited by 293
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 293
Natural killer cells in liver disease
Tian, Z., Chen, Y., & Gao, B. (2013) · Hepatology · doi:10.1002/hep.26115 · Cited by 290
Zhang, J., Zhang, Q., Lou, Y., Fu, Q., Chen, Q., Wei, T., Yang, J., Tang, J., Wang, J., Chen, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29681 · Cited by 286
Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
Dardalhon, V., Anderson, A. C., Karman, J., Apetoh, L., Chandwaskar, R., Lee, D. H., Cornejo, M., Nishi, N., Yamauchi, A., Quintana, F. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903275 · Cited by 278
Kuang, D.-M., Peng, C., Zhao, Q., Wu, Y., Chen, M.-S., & Zheng, L. (2010) · Hepatology · doi:10.1002/hep.23291 · Cited by 263
Zheng, J., Cai, J., Li, H., Zeng, K., He, L., Fu, H., Zhang, J., Chen, L., Yao, J., Zhang, Y., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485396 · Cited by 260
Comprehensive molecular and immunological characterization of hepatocellular carcinoma
Shimada, S., Mogushi, K., Akiyama, Y., Furuyama, T., Watanabe, S., Ogura, T., Ogawa, K., Ono, H., Mitsunori, Y., Ban, D., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.058 · Cited by 257
Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC
Pinyol, R., Sia, D., & Llovet, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3778 · Cited by 249 · cited 1×
“Although the frequency of WNT/β-catenin-mutated HCC, 20–30%, is not high [161,162], MTAs rather than ICIs may be suitable as a first-line treatment for WNT/βcatenin-mutated HCC.”
BackgroundChew, V., Lai, L., Pan, L., Lim, C. J., Li, J., Ong, R., Chua, C., Leong, J. Y., Lim, K. H., Toh, H. C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706559114 · Cited by 248
Jeong, W., Park, O., & Gao, B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.09.034 · Cited by 247
The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity
Elvevold, K., Smedsrød, B., & Martinez, I. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00167.2007 · Cited by 247
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
Khan, S., & Gerber, D. E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.012 · Cited by 241
Chen, K.-J., Lin, S.-Z., Zhou, L., Xie, H.-Y., Zhou, W.-H., Taki-Eldin, A., & Zheng, S.-S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024671 · Cited by 240
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Iñarrairaegui, M., Melero, I., & Sangro, B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0289 · Cited by 235
Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., et al. (2014) · Hepatology · doi:10.1002/hep.26694 · Cited by 226
Zhou, S., Yin, D., Hu, Z., Luo, C., Zhou, Z., Xin, H., Yang, X., Shi, Y., Wang, Z., Huang, X., et al. (2019) · Hepatology · doi:10.1002/hep.30630 · Cited by 226
Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
Osa, A., Uenami, T., Koyama, S., Fujimoto, K., Okuzaki, D., Takimoto, T., Hirata, H., Yano, Y., Yokota, S., Kinehara, Y., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.59125 · Cited by 223
Keenan, B. P., Fong, L., & Kelley, R. K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0749-z · Cited by 220
Human Liver Dendritic Cells Promote T Cell Hyporesponsiveness
Bamboat, Z. M., Stableford, J. A., Plitas, G., Burt, B. M., Nguyen, H. M., Welles, A. P., Gonen, M., Young, J. W., & DeMatteo, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803404 · Cited by 213
Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials
Harsha, C., Banik, K., Ang, H. L., Girisa, S., Vikkurthi, R., Parama, D., Rana, V., Shabnam, B., Khatoon, E., Kumar, A. P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093285 · Cited by 212
Qasim, W., Brunetto, M., Gehring, A. J., Xue, S.-A., Schurich, A., Khakpoor, A., Zhan, H., Ciccorossi, P., Gilmour, K., Cavallone, D., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.001 · Cited by 208
Greten, T. F., Forner, A., Korangy, F., N'Kontchou, G., Barget, N., Ayuso, C., Ormandy, L. A., Manns, M. P., Beaugrand, M., & Bruix, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-209 · Cited by 208
Dong, P., Ma, L., Liu, L., Zhao, G., Zhang, S., Dong, L., Xue, R., & Chen, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030320 · Cited by 207
Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., Lin, S., Wang, S., Wu, Q., Liang, Q., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00690 · Cited by 207
Neutrophils as active regulators of the immune system in the tumor microenvironment
Shaul, M. E., & Fridlender, Z. G. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5mr1216-508r · Cited by 203
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma
Sun, C., Sun, H., Zhang, C., & Tian, Z. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.91 · Cited by 200
Jiang, H., Rivera-Molina, Y., Gomez-Manzano, C., Clise-Dwyer, K., Bover, L., Vence, L. M., Yuan, Y., Lang, F. F., Toniatti, C., Hossain, M. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0468 · Cited by 197
Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051089 · Cited by 197
Park, O., Jeong, W.-I., Wang, L., Wang, H., Lian, Z.-X., Gershwin, E. M., & Gao, B. (2009) · Hepatology · doi:10.1002/hep.22813 · Cited by 189
Deng, Y., Cheng, J., Fu, B., Liu, W., Chen, G., Zhang, Q., & Yang, Y. (2017) · Oncogene · doi:10.1038/onc.2016.273 · Cited by 186
Kapanadze, T., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.010 · Cited by 185
Yu, M., Luo, H., Fan, M., Wu, X., Shi, B., Di, S., Liu, Y., Pan, Z., Jiang, H., & Li, Z. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.012 · Cited by 185
Wang, D., Yang, L., Yue, D., Cao, L., Li, L., Wang, D., Ping, Y., Shen, Z., Zheng, Y., Wang, L., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.040 · Cited by 183
Dendritic cells and immune regulation in the liver
Lau, A. H. (2003) · Gut · doi:10.1136/gut.52.2.307 · Cited by 183
Liver natural killer cells: subsets and roles in liver immunity
Peng, H., Wisse, E., & Tian, Z. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.96 · Cited by 181
Liu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K.-W., Sun, H., Zeng, X., Tang, W., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317257 · Cited by 176
NKT cell subsets as key participants in liver physiology and pathology
Bandyopadhyay, K., Marrero, I., & Kumar, V. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.115 · Cited by 175
Katz, S. C., Bamboat, Z. M., Maker, A. V., Shia, J., Pillarisetty, V. G., Yopp, A. C., Hedvat, C. V., Gonen, M., Jarnagin, W. R., Fong, Y., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2668-9 · Cited by 171
Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma
Yang, X. H., Yamagiwa, S., Ichida, T., Matsuda, Y., Sugahara, S., Watanabe, H., Sato, Y., Abo, T., Horwitz, D. A., & Aoyagi, Y. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.01.036 · Cited by 164
Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma
Zhang, W., He, H., Zang, M., Wu, Q., Zhao, H., Lu, L.-L., Ma, P., Zheng, H., Wang, N., Zhang, Y., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.024 · Cited by 163
Michaeli, J., Shaul, M. E., Mishalian, I., Hovav, A.-H., Levy, L., Zolotriov, L., Granot, Z., & Fridlender, Z. G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356965 · Cited by 159
Yao, W., Ba, Q., Li, X., Li, H., Zhang, S., Yuan, Y., Wang, F., Duan, X., Li, J., Zhang, W., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.07.014 · Cited by 157
Atezolizumab: First Global Approval
Markham, A. (2016) · Drugs · doi:10.1007/s40265-016-0618-8 · Cited by 156
Zhou, Z., Wang, P., Sun, R., Li, J., Hu, Z., Xin, H., Luo, C., Zhou, J., Fan, J., & Zhou, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001946 · Cited by 153
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis
Gäbele, E., Mühlbauer, M., Dorn, C., Weiß, T. S., Froh, M., Schnabl, B., Wiest, R., Schölmerich, J., Obermeier, F., & Hellerbrand, C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.096 · Cited by 150
Tan, A. T., Yang, N., Krishnamoorthy, T. L., Oei, V., Chua, A., Zhao, X., Tan, H. S., Chia, A., Bert, N. L., Low, D. H. P., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.251 · Cited by 150
Qin, S., Finn, R. S., Kudo, M., Meyer, T., Vogel, A., Ducreux, M. P., Macarulla, T. M., Tomasello, G., Boisserie, F., Hou, J. W.-S., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0097 · Cited by 149
Adipocytokines and hepatic fibrosis
Saxena, N. K., & Anania, F. A. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.01.002 · Cited by 142
Li, F., Zhao, Y., Wei, L., Li, S., & Liu, J. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1450116 · Cited by 140
Liu, P., Chen, L., & Zhang, H. (2018) · Journal of Immunology Research · doi:10.1155/2018/1206737 · Cited by 140
Liu, C., Liu, L., Chen, X., Cheng, J., Zhang, H., Zhang, C., Shan, J., Shen, J., & Qian, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1236 · Cited by 139
How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions
Bruger, A. M., Dorhoi, A., Esendağlı, G., Barczyk‐Kahlert, K., van der Bruggen, P., Lipoldová, M., Perečko, T., Santibanez, J. F., Saraiva, M., Ginderachter, J. A. V., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2170-8 · Cited by 137
Krämer, B., Körner, C., Kebschull, M., Glässner, A., Eisenhardt, M., Nischalke, H. D., Alexander, M., Sauerbruch, T., Spengler, U., & Nattermann, J. (2012) · Hepatology · doi:10.1002/hep.25804 · Cited by 133
Lurje, I., Hammerich, L., & Tacke, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197378 · Cited by 126
The stellate cell system (vitamin A-storing cell system)
Senoo, H., Mezaki, Y., & Fujiwara, M. (2017) · Anatomical Science International · doi:10.1007/s12565-017-0395-9 · Cited by 123
Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A meta-analysis
Ding, W., Xu, X., Qian, Y., Xue, W., Wang, Y., Du, J., Jin, L., & Tan, Y. (2018) · Medicine · doi:10.1097/md.0000000000013301 · Cited by 123
The Role of Sinusoidal Endothelial Cells in the Axis of Inflammation and Cancer Within the Liver
Wilkinson, A. L., Qurashi, M., & Shetty, S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00990 · Cited by 121
Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics
Kitao, A., Matsui, O., Yoneda, N., Kozaka, K., Kobayashi, S., Sanada, J., Koda, W., Minami, T., Inoue, D., Yoshida, K., et al. (2015) · Radiology · doi:10.1148/radiol.14141315 · Cited by 109
Cho, H., Kang, H., Lee, H., & Kim, C. W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071517 · Cited by 104
Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 104
Qu, J., Yuan, Z., Wang, G., Wang, X., & Li, K. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.02.016 · Cited by 103
Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling
Li, Y., Wang, R., Xiong, S., Wang, X., Zhao, Z., Bai, S., Wang, Y., Zhao, Y., & Cheng, B. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1731-9 · Cited by 101
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer
Xie, C., Duffy, A. G., Mabry‐Hrones, D., Wood, B. J., Levy, E. B., Krishnasamy, V. P., Khan, J. I., Wei, J. S., Agdashian, D., Tyagi, M. G., et al. (2018) · Hepatology · doi:10.1002/hep.30482 · Cited by 101
Rhee, H., Kim, H., Choi, J. H., Woo, H. G., Yoo, J. E., Nahm, J. H., Choi, J.-S., & Park, Y. N. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0988 · Cited by 99
Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 99
SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis
Natarajan, V., Harris, E. N., & Kidambi, S. (2017) · BioMed Research International · doi:10.1155/2017/4097205 · Cited by 98
Gong, Y., & Yang, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117909 · Cited by 82
Li, L., Yan, J., Xu, J., Liu, C.-Q., Zhen, Z. J., Chen, H., Ji, Y., Wu, Z.-P., Hu, J. Y., Zheng, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110064 · Cited by 79
ARID2 modulates DNA damage response in human hepatocellular carcinoma cells
Oba, A., Shimada, S., Akiyama, Y., Nishikawaji, T., Mogushi, K., Ito, H., Matsumura, S., Aihara, A., Mitsunori, Y., Ban, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.026 · Cited by 79
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
Brunetti, O., Gnoni, A., Licchetta, A., Longo, V., Calabrese, A., Argentiero, A., Delcuratolo, S., Solimando, A. G., Gardini, A. C., & Silvestris, N. (2019) · Medicina · doi:10.3390/medicina55100707 · Cited by 75
Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials
Kudo, M. (2019) · Liver Cancer · doi:10.1159/000501501 · Cited by 71
The role of liver sinusoidal cells in local hepatic immune surveillance
Wohlleber, D., & Knolle, P. A. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.74 · Cited by 70
Oh, C. R., Kong, S., Im, H.-S., Kim, H. J., Kim, M. K., Yoon, K., Cho, E., Jang, J.-H., Lee, J., Kang, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5483-x · Cited by 68
Tsuchiya, K., Asahina, Y., Matsuda, S., Muraoka, M., Nakata, T., Suzuki, Y., Tamaki, N., Yasui, Y., Suzuki, S., Hosokawa, T., et al. (2013) · Cancer · doi:10.1002/cncr.28384 · Cited by 64
Specific CD8+T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis
Moreno-Cubero, E., & Larrubia, J. R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6469 · Cited by 63
Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review
Kadota, H., Gono, T., Shirai, Y., Okazaki, Y., Takeno, M., & Kuwana, M. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0811-3 · Cited by 63
Wu, C.-J., Tsai, Y.-T., Lee, I., Wu, P., Lu, L., Tsao, W.-S., Huang, Y.-J., Chang, C.-C., Ka, S., & Tao, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1477459 · Cited by 61
Ramzan, M., Stürm, N., Decaens, T., Bioulac‐Sage, P., Bancel, B., Merle, P., Nhieu, J. T. V., Slama, R., Létoublon, C., Zarski, J., et al. (2015) · Liver International · doi:10.1111/liv.12927 · Cited by 59
Lee, H. W., Cho, K. J., & Park, J. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e11 · Cited by 59
CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice
Ishikawa, S., Ikejima, K., Yamagata, H., Aoyama, T., Kon, K., Arai, K., Takeda, K., & Watanabe, S. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.022 · Cited by 57
Wang, F., Jing, X., Li, G., Wang, T., Yang, B., Zhu, Z., Gao, Y., Zhang, Q., Yang, Y., Wang, Y., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02675.x · Cited by 55
Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease
Jia, L., Chang, X., Qian, S., Liu, C., Lord, C. C., Ahmed, N., Lee, C. E., Lee, S., Gautron, L., Mitchell, M. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.015 · Cited by 54
Koh, M. Y., Gagea, M., Sargis, T., Lemos, R., Grandjean, G. V., Charbono, A., Bekiaris, V., Šedý, J. R., Kiriakova, G. M., Liu, X., et al. (2016) · Hepatology · doi:10.1002/hep.28468 · Cited by 53
Patten, D., Wilson, G., Bailey, D., Shaw, R., Jalkanen, S., Salmi, M., Rot, A., Weston, C. J., Adams, D., & Shetty, S. (2016) · Hepatology · doi:10.1002/hep.28879 · Cited by 52
Wang, X., Deng, B., & Sun, Z. (2018) · Journal of Molecular Modeling · doi:10.1007/s00894-018-3886-2 · Cited by 52
Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
Cui, T., Liu, Y., Wang, J.-B., & Liu, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s279858 · Cited by 52
Malik, A., Thanekar, U., Amarachintha, S. P., Mourya, R., Nalluri, S., Bondoc, A. J., & Shivakumar, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.627701 · Cited by 48
Shao, Y., Huang, C.-C., Lin, S.-D., Hsu, C., & Cheng, A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2853 · Cited by 46
Wang, X., & Tian, Z. (2018) · Frontiers of Medicine · doi:10.1007/s11684-017-0584-x · Cited by 44
Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches
Tagliamonte, M., Mauriello, A., Cavalluzzo, B., Ragone, C., Manolio, C., Petrizzo, A., & Buonaguro, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.029 · Cited by 44
Roles of the inflammasome in the gut‑liver axis (Review)
Wang, J., Dong, R., & Zheng, S. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9679 · Cited by 43
Koyama, N., Saito, K., Nishioka, Y., Yusa, W., Yamamoto, N., Yamada, Y., Nokihara, H., Koizumi, F., Nishio, K., & Tamura, T. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-530 · Cited by 42
Mamrot, J., Balachandran, S., Steele, E. J., & Lindley, R. A. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12760 · Cited by 42
Lee, C.-H., Lee, Y. B., Kim, M. A., Jang, H., Oh, H., Kim, S. W., Cho, E. J., Lee, K.-H., Lee, J., Yu, S. J., et al. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2019.0049n · Cited by 42
Pattern Recognition Receptors: Significance of Expression in the Liver
Zeromski, J., Kierepa, A., Brzezicha, B., Kowala-Piaskowska, A. E., & Mozer‐Lisewska, I. (2020) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-020-00595-1 · Cited by 41
Second-line treatment options in hepatocellular carcinoma
Marino, D., Zichi, C., Audisio, M., Sperti, E., & Maïo, M. D. (2019) · Drugs in Context · doi:10.7573/dic.212577 · Cited by 40
Mano, Y., Yoshio, S., Shoji, H., Shimagaki, T., Aoki, Y., Aoyanagi, N., Okamoto, T., Matsuura, Y., Osawa, Y., Kimura, K., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01579-5 · Cited by 39
PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review
Voutsadakis, I. A. (2019) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2019.09.007 · Cited by 39
Wang, Y., Huang, F., Cai, H., Zhong, S., Liu, X., & Tan, W. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1177 · Cited by 35
T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC
Szöőr, Á., Vaidya, A. B., Velasquez, M. P., Mei, Z., Galvan, D. L., Torres, D., Gee, A. P., Heczey, A. A., & Gottschalk, S. M. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.07.002 · Cited by 34
Rong, Y., Wan, Z., Song, H., Li, Y. ‐., Zhu, B., Zang, H., Zhao, Y., Liu, H. ‐., Zhang, A. ‐., Xiao, L., et al. (2014) · Tissue Antigens · doi:10.1111/tan.12278 · Cited by 33
Wang, Q., Yu, T., Yuan, Y., Zhuang, H., Wang, Z., Liu, X.-S., & Feng, M. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23227 · Cited by 32
Joerger, M., Güller, U., Bastian, S., Driessen, C., & von Moos, R. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.11.04 · Cited by 32
Bacterial infections in cirrhosis: Current treatment
Miranda-Zazueta, G., de León-Garduño, L. A. P., Aguirre-Valádez, J., & Torre-Delgadillo, A. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.09.011 · Cited by 28
A killer choice for cancer immunotherapy
Schmidt, T. L., Negrin, R. S., & Contag, C. H. (2014) · Immunologic Research · doi:10.1007/s12026-014-8507-2 · Cited by 26
Tada, Y., Yoshikawa, T., Shimomura, M., SAWADA, Y., Sakai, M., Shirakawa, H., Nobuoka, D., & Nakatsura, T. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2044 · Cited by 26
Faloppi, L., Puzzoni, M., Gardini, A. C., Silvestris, N., Masi, G., Marisi, G., Vivaldi, C., Gadaleta, C. D., Ziranu, P., Bianconi, M., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00698-x · Cited by 23
Li, H., Li, H., Li, X., Zou, H., Liu, L., Liu, W., & Duan, T. (2018) · Oncology Reports · doi:10.3892/or.2018.6660 · Cited by 15
Natural Killer T Cells in Various Mouse Models of Hepatitis
Guan, J., Wang, G., Yang, Q., Chen, C., Deng, J., Gu, X., & Zhu, H. (2021) · BioMed Research International · doi:10.1155/2021/1782765 · Cited by 11
Cited by
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 667
Pang, K., Shi, Z.-D., Wei, L.-Y., Dong, Y., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J.-J., Chen, Y.-A., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100907 · Cited by 260
Ma, Y., Guo, C., Wang, X., Wei, X., & Ma, J. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02804-z · Cited by 29
Metadata
- Authors
- Oura, K., Morishita, A., Tani, J., & Masaki, T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-05-28
- Volume
- 22
- Issue
- 11
- Pages
- 5801
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3164582693
- Cited by
- 426
- References
- 199
- FWCI
- 23.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.